Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
28 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Arizona at Dignity Health St. Joseph'S
Phoenix, Arizona, United States
- City of Hope Comprehensive Cancer Center
Duarte, California, United States
- University of Southern California
Los Angeles, California, United States
- Georgetown University
Washington D.C., District of Columbia, United States
- University of Florida
Gainesville, Florida, United States
- Iu Health Goshen Center for Cancer Care
Goshen, Indiana, United States
- Community Regional Cancer Care
Indianapolis, Indiana, United States
- Iu Health Central Indiana Cancer Center
Indianapolis, Indiana, United States
- Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, United States
- Community Healthcare System
Munster, Indiana, United States
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States
- University of Maryland
Baltimore, Maryland, United States
- Henry Ford Health System
Detroit, Michigan, United States
- University of Minnesota
Minneapolis, Minnesota, United States
- Washington University: Siteman Cancer Center
St Louis, Missouri, United States
- Gu Cancer Research Network, Llc
Omaha, Nebraska, United States
- the John Theuer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, United States
- University of New Mexico Cancer Center
Albuquerque, New Mexico, United States
- Roswell Park Cancer Institute
Buffalo, New York, United States
- Tisch Cancer Institute at Mount Sinai Medical Center
New York, New York, United States
- University of Rochester Medical Center
Rochester, New York, United States
- University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
- Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
- Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
- Medical University of South Carolina
Charleston, South Carolina, United States
- Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
- Huntsman Cancer Institute University of Utah
Salt Lake City, Utah, United States
- Virginia Oncology Associates
Norfolk, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 11 Nov 2015
- Primary completion
- 1 Jul 2019
- Completion
- 1 Jan 2021
- Last update posted
- 30 Sept 2022
- Registered enrollment
- 108
- Registry id
- NCT02500121
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.